IFNL3抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human ovarian cancer tissue, Primary antibody: P08438(IFNL3 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

Interferon lambda 3 (IFNL3), also known as interleukin-28B (IL-28B), is a cytokine belonging to the type III interferon family. It plays a critical role in antiviral immune responses, particularly against hepatitis C virus (HCV) and other viral infections. IFNL3 signals through a heterodimeric receptor complex composed of IFNLR1 and IL-10Rβ, activating the JAK-STAT pathway to induce interferon-stimulated genes (ISGs) that inhibit viral replication. Genetic polymorphisms near the *IFNL3* gene, notably rs12979860. are strongly associated with spontaneous and treatment-induced clearance of HCV, making it a key biomarker in predicting therapeutic outcomes.

Antibodies targeting IFNL3 or its receptor have been developed to study its biological functions and therapeutic potential. In research, anti-IFNL3 antibodies are used to block its activity, helping elucidate its role in immune regulation, viral persistence, and inflammatory diseases. Clinically, IFNL3 has been explored as a therapeutic target, particularly in chronic hepatitis and autoimmune conditions. For example, neutralizing antibodies could modulate excessive interferon signaling linked to tissue damage, while agonist antibodies might enhance antiviral responses. However, challenges remain, including understanding tissue-specific effects and managing interindividual variability due to genetic factors. IFNL3 antibodies thus represent a dual tool for dissecting immune mechanisms and developing targeted therapies in virology and immunology.